Skip to content
Medical Health Aged Care

DNP to Take Controlling-Stake in Laxton

Dai Nippon Printing Co., Ltd. 2 mins read

Maximizing synergies to accelerate the global expansion of biometric info-driven government authentication and security business


TOKYO--BUSINESS WIRE--

Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) entered into a share transfer agreement on June 17, 2025 to acquire Cayman Islands-headquartered Rubicon SEZC. Rubicon (a holding company of “Laxton” group) is a global Identity Systems Integrator that provides ID solutions for governments, primarily in developing nations, to register and authenticate personal information. DNP plans to acquire 75% of Rubicon's shares in July and complete the procedures to make the company a Group company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613922077/en/

Products of Laxton

Products of Laxton

DNP will maximize synergies with Laxton in ID cards and card printers. By expanding to government-related business in Africa, Asia, South America, and other regions, we will further grow our authentication and security business, contributing to a safe and secure Smart Society.

[About Laxton]

Laxton develops ID authentication services using biometric information, primarily for governments in emerging countries and regions, such as Africa, and has a track record of implementation in over 50 countries and regions around the world. The company provides services that combine mobility, robustness, and security by housing ID registration and authentication devices and card printers in a portable case. Laxton provides one-stop services ranging from consulting to development, implementation, training, and maintenance to meet the needs of governments and other organizations, and has earned a high reputation in countries and regions around the world.

[Major Synergies from Laxton Acquisition]

  • Service improvement-driven business expansion
  • Expanding to emerging countries and regions where market growth is expected

[Going Forward]

DNP will seek to maximize synergies between our two companies through this acquisition, and aims to achieve cumulative sales of 140 billion yen by FY 2030 via ID authentication services for overseas governments.

More Details

About DNP

DNP was established in 1876, and has become a leading global company that leverages print-based solutions to engineer fresh business opportunities while protecting the environment and creating a more vibrant world for all. We capitalize on core competencies in microfabrication and precision coating technology to provide products for the display, electronic device, and optical film markets.


Contact details:

Media contact
DNP: Yusuke Kitagawa, +81-3-6735-0101
[email protected]

Media

More from this category

  • Medical Health Aged Care
  • 12/12/2025
  • 10:11
Cosette Pharmaceuticals, Inc.

Termination of Proposed Acquisition of Mayne Pharma

BRIDGEWATER, N.J.–BUSINESS WIRE– Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on…

  • Contains:
  • Medical Health Aged Care
  • 12/12/2025
  • 08:55
Royal Australian College of GPs

Universal Health Coverage Day: RACGP calls out need for better funding for chronic conditions and preventive care

Specialist GPs have marked International Universal Health Coverage (UHC) Day by joining the World Health Organization in highlighting the devastating impact of health costs. The Royal Australian College of GPs (RACGP) has stressed that a public health system which forces patients with complex or chronic conditions to pay out of pocket for longer consultations can’t claim to offer universal coverage, and urged governments to protect patients from financial hardship. “Health is a human right,” RACGP President Dr Michael Wright said. “Australia recognises the right of everyone to the highest attainable standard of physical and mental health, and our governments are…

  • Contains:
  • Medical Health Aged Care, Women
  • 12/12/2025
  • 01:00
Breast Cancer Trials

Simple blood tests could help tailor treatment for aggressive breast cancer

Key Facts: Blood tests detecting circulating tumour DNA could help guide treatment for triple negative breast cancer patients Absence of tumour DNA in blood…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.